The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.

An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...

Mattamy Homes, the largest privately owned homebuilder in North America, is pleased to announce the acquisition of 4.1 acres of prime real estate in the established master-planned community of Rocking ...

Today, the Government of Canada announced more than $40 million in contributions and low-cost repayable loans to build and repair 149 homes through eight housing projects located in Northern ...

Privately-held Menarini is paying up to $677 million for Stemline and Elzonris (tagraxofusp-erzs), the biotech’s treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), which was ...

An expert discusses how, historically, blastic plasmacytoid dendritic cell neoplasm (BPDCN) was treated with regimens for acute leukemia or lymphoma. Current NCCN guidelines recommend intensive ...

Star Equity Holdings, Inc. is a diversified holding company with three divisions: Building Solutions, Energy Services, and ...

After hours: March 7 at 6:48:39 p.m. EST Loading Chart for ANAB ...

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD. The pCR was 37.3% (95% ...